Three signals on NKE are moving in different directions at once. Short sellers have been unwinding positions. The cost to borrow has spiked sharply. And options traders are leaning more defensive. The divergence matters with June 25 earnings now five weeks out.
Short interest has fallen 15% over the past month — from roughly 58 million shares in mid-April to 49.4 million now. SI % of free float stands at 4.16%. That's a meaningful pullback in bearish positioning, though the level still represents genuine directional conviction rather than incidental hedging.
The short score has eased alongside it. It sits at 37.5 today, down from 40.6 two weeks ago. The ORTEX short score percentile rank of 41 places NKE in the lower half of the market — not an extreme read in either direction.
The stock itself has bounced. NKE closed Wednesday at $44.19, up 4.2% on the day and 4.4% on the week. That follows a brutal 34% year-to-date drawdown. Some of the short covering likely reflects that price recovery rather than a fundamental change in view.
Despite shorts pulling back, the cost to borrow has doubled in a week. CTB hit 0.48% on May 20 — up 93% from 0.25% seven days earlier. That's the sharpest weekly move since late April.
In absolute terms, 0.48% is still cheap. Borrowing NKE shares costs almost nothing. The lending market remains wide open: availability sits above 1,100% — meaning more than eleven shares are available to borrow for every one currently lent out. This is a loose borrow market by any measure. The CTB jump is notable as a directional signal, not as evidence of a supply squeeze.
The put-call ratio stands at 0.74, near the top of its 20-day range. The 52-week PCR range for NKE runs from 0.62 to 0.97 — so 0.74 is elevated relative to the recent mean of 0.74 but far from extreme. Options positioning reflects caution, not alarm.
Mean analyst price target is $60.78 — 37% above current levels. But the consensus is "hold," and the recent changes have been uniformly negative: Wells Fargo, Goldman Sachs, JP Morgan, HSBC and Piper Sandler all downgraded or cut targets since April 1. The Street is not yet buying the recovery thesis.
Capital Research added 9.6 million shares in the most recent reporting period. Wellington added 6.6 million. Those are meaningful institutional builds at depressed prices — echoing the April insider cluster noted in yesterday's article, where CEO Elliott Hill and Lead Independent Director Tim Cook both bought near $42.
The setup heading into June 25: shorts reducing, institutions adding, borrow costs ticking up despite ample supply, and options traders hedging a stock that has already lost a third of its value. The last two earnings prints moved NKE -12.9% and -2.1% on day one.
Watch: whether the CTB trend continues rising even as shorts unwind — that combination would suggest new short demand is entering at the same time existing sellers exit.
See the live data behind this article on ORTEX.
Open NKE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
